Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ariel R. Topletz-Erickson"'
Autor:
Ariel R. Topletz-Erickson, JoAl G. Mayor, Hsu-Tai Liu, Layth I. Abdulrasool, Christopher J. Endres
Publikováno v:
Drugs in R&D, Vol 23, Iss 4, Pp 411-419 (2023)
Abstract Background and Objective Tucatinib is a selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved to treat metastatic HER2-positive breast and colorectal cancers. The International Council for Harmon
Externí odkaz:
https://doaj.org/article/7a4ad461bb6c4392b531e81c99da3f67
Autor:
Ariel R, Topletz-Erickson, Anthony J, Lee, JoAl G, Mayor, Hao, Sun, Layth I, Abdulrasool, Evelyn L, Rustia, Luke N, Walker, Christopher J, Endres
Publikováno v:
Clinical Pharmacokinetics. 61:1761-1770
Tucatinib, a highly selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved for HER2-positive metastatic breast cancer, is cleared by hepatic metabolism and subsequent biliary excretion. Liver disease can a
Autor:
Ariel R. Topletz-Erickson, Anthony Lee, Vineet Kumar, Michelle Ubowski, JoAl G. Mayor, Layth I. Abdulrasool, Clark M. Henderson, Joseph A. Ware, Christopher J. Endres
Publikováno v:
Cancer Research. 83:5060-5060
Background: Oxaliplatin (OX)-containing regimens are frequently utilized to treat gastrointestinal (GI) cancers. OX is eliminated predominately via urinary excretion (GFR and active tubular secretion). The contribution of active transport via OCT2 an
Autor:
Evelyn Rustia, Amanda L. Wise, Sharon DeChenne, Ariel R. Topletz-Erickson, JoAl Mayor, Anthony Lee, Luke Walker, Ben Dailey, Layth I. Abdulrasool, Christopher J. Endres, Stephen C. Alley
Publikováno v:
Journal of Clinical Pharmacology
Tucatinib is a potent tyrosine kinase inhibitor selective for human epidermal growth factor receptor 2 (HER2) approved by the US Food and Drug Administration for the treatment of HER2‐positive metastatic breast cancer and in development for other H
Autor:
Evelyn Rustia, JoAl Mayor, Anthony J. Lee, Ariel R. Topletz-Erickson, Luke Walker, Hao Sun, Layth I. Abdulrasool, Christopher J. Endres
Publikováno v:
Cancer Research. 81:1371-1371
Background: Tucatinib (TUKYSA®) is a selective HER2-targeted tyrosine kinase inhibitor indicated in combination with trastuzumab and capecitabine for adult patients with metastatic HER2+ breast cancer who have received ≥1 prior HER2-based regimen,
Autor:
Luke Walker, Layth I. Abdulrasool, Evelyn Rustia, Ariel R. Topletz-Erickson, JoAl Mayor, Christopher J. Endres, Anthony Lee
Publikováno v:
Cancer Research. 80:3015-3015
Background: Tucatinib (TUC) is a potent, highly selective investigational HER2 tyrosine kinase inhibitor in development for treatment of patients with HER2+ metastatic breast cancer (MBC). In HER2CLIMB (H2C), a pivotal study of patients with HER2+ MB
Autor:
JoAl Mayor, Ariel R. Topletz-Erickson, Christopher J. Endres, Hao Sun, Luke Walker, Anthony Lee
Publikováno v:
Cancer Research. 80:3016-3016
Background: Tucatinib is a potent, highly selective HER2 tyrosine kinase inhibitor in development for the treatment of patients with HER2+ metastatic breast cancer. In vitro metabolism studies suggest that drug metabolizing enzymes CYP2C8 and CYP3A p